| Date | Title | | | 12/18/14 | Cipher Pharmaceuticals Inc. Announces Adoption of Advance Notice By-Law | Toronto Stock Exchange Symbol: CPH
NASDAQ Symbol: CPHRMISSISSAUGA, ON, Dec. 18, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (the "Company") (TSX: CPH; NASDAQ: CPHR) ("Cipher" or "the Company") announced today that its Board of Directors has approved a By-Law (the "Advance Notice By-Law") that requires advance notice to the Company where director nominations are made by shareholders of the Company, subject to specified exceptions. The Advance Notice By-law is similar to the Advance notice by-laws a... |
|  | | 12/03/14 | Shawn Patrick O’Brien, President & CEO of Cipher Pharamceuticals discusses the Company's NASDAQ listing on BNN | 12/03/2014Download this Press Release ()Shawn Patrick O’Brien, President and CEO of Cipher Pharmaceuticals recently appeared on BNN to discuss the Company's NASDAQ listing. To watch the full video, please see below:... |
| | | 11/25/14 | Cipher Pharmaceuticals to present at Piper Jaffray Healthcare Conference 2014 | MISSISSAUGA, ON, Nov. 25, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference in New York City. Cipher is scheduled to present on Tuesday, December 2, 2014 at10:00 AM ET.Cipher's presentation will be webcast live and may be accessed from the Investor Relations section of the Company's website at www.cipherpharma.com.About Cipher Pharma... |
| | | 11/20/14 | Cipher Pharmaceuticals to commence trading on the NASDAQ Global Market | Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, Nov. 20, 2014 /CNW/ - Cipher Pharmaceuticals Inc. ("Cipher" or the "Company") (TSX:DND, NASDAQ:CPHR) today announced that its common shares have been approved for listing and trading on the NASDAQ Global Market (the "NASDAQ") commencing at the start of trading on November 24, 2014, under the trading ticker symbol "CPHR".Cipher's common shares will continue to be listed in Canada on the Toronto Stock Exchange, however, the Company's ticker symbol... |
| | | 10/29/14 | Cipher Reports Financial Results for Q3 2014 | - Company also announces application to list on NASDAQ -Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, Oct. 29, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and nine months ended September 30, 2014. Q3 2014 HighlightsTotal revenue of $7.2 million, an increase of 28% compared with $5.6 million in Q3 2013. EBITDA1 rose 37% to $5.2 million versus $3.8 million in Q3 2013. Net income was $8.7 million, or $0.34 per basic sh... |
| | | 10/20/14 | Notice of Cipher Pharmaceuticals Inc. Q3 2014 Conference Call | Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, Oct. 20, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), today announced it will host a conference call for its Q3 2014 financial results on Wednesday, October 29, 2014.Q3 2014 CONFERENCE CALLWHEN: Wednesday, October 29, 2014 at 8:30AM ETCONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through http://www.cipherpharma.com or http://bit.ly/1nx9i5o an ... |
| | | 10/01/14 | Ranbaxy Launches Absorica® (Isotretinoin) 25 mg and 35 mg Capsules in the U.S. Market | | | 09/03/14 | Cipher Pharmaceuticals Inc. to present at Rodman & Renshaw 16th Annual Global Investment Conference | MISSISSAUGA, ON, Sept. 3, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced Shawn Patrick O'Brien, President and Chief Executive Officer, is presenting at the Rodman & Renshaw 16th Annual Global Investment Conference, which is being held in New York City from September 8-10 at the New York Palace Hotel. Mr. O'Brien will provide a corporate update and participate in a Q&A breakout session on Tuesday, September 9, 2014 at 9:35 AM ET in the Holm... |
| | | 07/30/14 | Cipher reports financial results for Q2 2014 | Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, July 30, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2014.Q2 2014 HighlightsTotal revenue of $8.7 million, an increase of 58% compared with $5.5 million in Q2 2013.Revenue from Absorica™ was $5.8 million, up from $4.1 million in Q2 2013.EBITDA1 rose to $6.5 million versus $3.5 million in Q2 2013.Net income was $4.5 million, or $0.18 per basi... |
| | | 07/24/14 | Cipher Pharmaceuticals and Ranbaxy Announce Distribution Agreement for Isotretinoin Product in Brazil | MISSISSAUGA, ON, July 24, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has entered into a definitive distribution and supply agreement with Ranbaxy Laboratories Ltd. ("Ranbaxy") under which Cipher has granted Ranbaxy the exclusive right to market, sell and distribute Cipher's isotretinoin capsules in Brazil. This agreement extends the current relationship with Ranbaxy, which markets and distributes Cipher's isotretinoin product in the United States under the brand Absor... |
| |
|
